U.S. markets closed

Scholar Rock Holding Corporation (SRRK)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
26.52-0.75 (-2.75%)
At close: 4:00PM EDT
26.52 0.00 (0.00%)
After hours: 04:00PM EDT

Scholar Rock Holding Corporation

301 Binney Street
3rd Floor
Cambridge, MA 02142
United States
857 259 3860

Full Time Employees119

Key Executives

NameTitlePayExercisedYear Born
Dr. Nagesh K. Mahanthappa MBA, Ph.D.Interim Chief Exec. Officer1.37MN/A1965
Mr. Edward H. Myles M.B.A., MBACFO & Head of Bus. Operations660.51kN/A1972
Dr. Gregory John Carven Ph.D.Chief Scientific Officer551.33kN/A1976
Ms. Catherine HuVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Ms. Junlin Ho J.D.Gen. Counsel & Corp. Sec.N/AN/A1979
Ms. Caryn ParlavecchioChief HR OfficerN/AN/AN/A
Dr. Yung H. Chyung M.D.Chief Medical OfficerN/AN/A1976
Ms. Lisa Amaya PriceSr. VP of HRN/AN/AN/A
Dr. George G. Nomikos M.D., Ph.D.Sr. VP of Medical & Clinical Sciences and Head of Muscle Therapeutic AreaN/AN/AN/A
Ms. Erin MooreSr. VP of Fin.N/AN/A1975
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Scholar Rock Holding Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, a novel inhibitor of the activation of latent myostatin that has completed the Phase II clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase I clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Scholar Rock Holding Corporation’s ISS Governance QualityScore as of September 26, 2021 is 9. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.